Next Generation Site-Specific Conjugation and Linker Technologies for ADCs

AJICAP®’s VALUE

Therapeutic Window Enhancement

  • ADCs with higher efficacy and lower toxicity achieved by site-specific conjugation and stable & hydrophilic linker

Straightforward Site-Specific Conjugation Method

  • Direct modification on native antibody by chemical method
  • No genetic engineering and no enzyme required
  • Simple and high yield manufacturing process
  • Precisely controlled DAR2 and higher

Applicable for Versatile ADCs

  • Site-specific conjugation applicable for any IgG molecule and a variety of payloads
  • Stable & hydrophilic linker compatible with various payloads

Index

Technology

AJICAP® Site-Specific Conjugation

AJICAP® site-specific conjugation is an innovative direct chemical site-specific conjugation method for intact native antibodies, offering significant advantages for next generation ADCs.

Image expansion
AJICAP® Site-Specific Conjugation consists of:

  1. Introduction of bio-orthogonal functionalities (thiol, azide etc) onto specific Lys residue in Fc region*

  2. Conjugation with
    linker-payload

* Site-specificity is derived from peptide in AJICAP® reagent binding to specific moiety in Fc region.
Advantage of AJICAP® Site-Specific Conjugation

  1. Higher efficacy and lower toxicity achieved due to site-specificity

  2. Simple manufacturing and purification process providing CMC advantage

  3. Precisely controlled DAR2 or higher DAR on specific sites

  4. Applicable for a wide variety of antibodies i.e. IgG1, IgG2 and IgG4

  5. Compatible with various payload-linkers i.e. small molecule to large molecule

Application of AJICAP® Site-Specific Conjugation:

  • ADC platform with various payloads (toxin and others)

  • In-vivo radio imaging/therapy platform with radioisotopes

  • Long-acting biopharmaceutical platform for peptides and oligonucleotides

  • Bispecific platform with proteins

Image expansion

AJICAP® Stable and and Hydrophilic Linker

AJICAP® linker is a novel stable and hydrophilic linker, applicable to various payloads, offering significant advantages for versatile ADCs.

Image expansion
Characteristics of AJICAP® stable and hydrophilic linker

  1. Higher serum stability and controlled release in cancer tissues

  2. Hydrophilic masking of payload

Advantage of AJICAP® Stable and Hydrophilic Linker

  1. Higher efficacy and lower toxicity achieved due to higher serum stability and controlled release in cancer tissues

  2. Dramatically lower aggregation of ADCs by hydrophilic masking of payloads

  3. Applicable for a variety of conjugation technologies including AJICAP® conjugation

Application of AJICAP® Stable and Hydrophilic Linker Technology:

Compatible with a variety of conjugation technologies including:

AJICAP® Site-Specific Conjugation Technology

Native Cys conjugation
DAR4-DAR8

Other genetic engineering and
enzymatic method

Biological Activity of AJICAP®-ADCs

ADCs generated by AJICAP® site-specific conjugation and stable & hydrophilic linker has higher efficacy and lower toxicity.

Global Service Offering

Service flow of AJICAP® is simple and easy. The following steps outline the process:

Service Flow

Service flow of AJICAP® is simple and easy. The following steps outline the process:

  • Research plan discussion

  • Client ships antibody (and payload) to Ajinomoto Bio-Pharma Services

  • Ajinomoto Bio-Pharma Services generates ADCs or other conjugates

  • Client evaluates ADCs or conjugates in vitro and in vivo

  • Technology license Go/No Go decision

  • GxP production discussion

Contact Us

For further information, please contact us using the link below and an Ajinomoto Bio-Pharma Services representative will contact you.